© 2024 Tolmar, Inc. All rights reserved. Tolmar, ELIGARD and their associated logos are trademarks of the Tolmar Group. Third-party
trademarks and product names belong to their respective owners. TPI.2023.4010.v2 01/24
Higher WAC products can cause a higher cost burden to patients
The impact of escalating costs on individual patients with prostate cancer
Cancer is one of the most expensive medical conditions to treat in the US and often leads to financial toxicity that can impact care.
- Cancer patients experiencing financial hardship are less likely to adhere to prescribed treatments and follow up, which could result in higher rates of cancer relapse and death.1
- According to the March 2023 edition of The Oncologist, out of 91 patients who consented to research, 50% of them reported their reason for not filling their prescription was due to cost.2
- For patients with cancer, the mean total out-of-pocket cost burden as a share of annual income was 24%. One in five prostate cancer patients reported a need to reduce spending or make sacrifices to afford treatment.3,4
Patient Cost Burden by Coverage Type*
If treatment cost is high, perhaps see if a similar, more responsibly priced product is available with similar efficacy and discuss with the provider if that alternative product is available and right for that patient.
Do you consider the financial side effect of the product you select when starting a patient on ADT?
ELIGARD has consistently had one of the lowest WACs in the LHRH market, ensuring that cost burden to the patient is kept as low as possible.
Tolmar is meeting the needs of patients and providers
Tolmar is committed to keeping ELIGARD responsibly priced to ensure access across healthcare systems, providers, and most importantly – patients
Patient Access Support
Practice Support
Clinical Support
Low OOP Expense
To learn more about ELIGARD’s proven efficacy and flexible dosing visit Eligardhcp.com
IMPORTANT SAFETY INFORMATION
ELIGARD®, (leuprolide acetate) for injectable suspension, is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of advanced prostate cancer.
ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.
Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.
ELIGARD may impair fertility in males of reproductive potential.
The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions,
including decreased bone density and rare cases of pituitary apoplexy have been reported. Please visit EligardHCP.com for full Prescribing and Safety Information
References:
1. Persaud N. Renal & Urology News, Urology, Prostate Cancer. https://www.renalandurologynews.com/home/news/urology/prostate-cancer/financial-toxicity-common-stressful-in-metastatic-prostate-cancer/ (visited August 20, 2023).
2. Bureau of Labor Statistics, U.S. Department of Labor, The Economics Daily, Consumer prices up 4.7 percent since February 2020 at https://www.bls.gov/opub/ted/2021/consumer-prices-up-4-7-percent-since-february-2020.htm (visited July 10, 2023).
3. Conti RM, et al. Reform Medicare Part B to improve affordability and equity. https://www.healthaffairs.org/do/10.1377/forefront.20210622.349716/full/. Accessed April 24, 2023.
4. Ginsburg PB, Lieberman SM. Medicare payment for physician-administered (Part B) drugs: the interim final rule and a better way forward. https://www.brookings.edu/blog/usc-brookings-schaeffer-on-health-policy/2021/02/10/medicare-payment-for-physician-administered-part-b-drugs/. Accessed April 21, 2023.
5. Even Insured Patients With Advanced Cancer Experience Financial Toxicity March 16, 2022 by Elisa Becze BA, ELS, Editor
6. Centers for Medicare & Medicaid Services. 2023 Medicare Parts A & B Premiums and Deductibles 2023 Medicare Part D Income-Related Monthly Adjustment Amounts (fact sheet). September 27, 2022. https://www.cms.gov/newsroom/fact-sheets/2023-medicare-parts-b-premiums-and-deductibles-2023-medicare-part-d-income-related-monthly.
7. Kaiser Family Foundation. An overview of the Medicare Part D prescription drug benefit. https://www.kff.org/medicare/fact-sheet/an-overview-of-the-medicare-part-d-prescription-drug-benefit/. Accessed April 13, 2023.
8. Kaiser Family Foundation. Employer Health Benefits: 2022 Annual Survey. San Francisco, CA: Kaiser Family Foundation; 2022.
9. Data on file, Tolmar, Inc.